Insights into gene therapy for critical limb ischemia: The devil is in the details

Rosalinda Madonna, Gregg Rokosh

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Patients with critical limb ischemia (CLI) without potential for revascularization are currently without alternate therapies. Several gene therapy trials have tested angiogenesis factors, hepatic growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, in rescuing CLI patients from amputation and mortality, and for improved quality of life including decreased pain, improved healing, and blood flow. Trial results have been variable, with HGF gene therapy being the most successful. New studies examining each of these angiogenic factors provide insights that will be useful for the design of effective therapeutic strategies.

Original languageEnglish
Pages (from-to)10-14
Number of pages5
JournalVascular Pharmacology
Issue number1
StatePublished - Aug 19 2012


  • Basic fibroblast growth factor
  • Critical limb ischemia
  • Gene therapy
  • Hepatocyte growth factor
  • Vascular endothelial growth factor


Dive into the research topics of 'Insights into gene therapy for critical limb ischemia: The devil is in the details'. Together they form a unique fingerprint.

Cite this